抗VEGFR-2嵌合Fab抗体对裸鼠肝癌原位移植瘤的治疗作用  

Therapeutical effect of chimeric anti-VEGFR-2 Fab antibody on orthotopic xenograft of hepatocellular carcinoma in BALB/c nude mice

作　　者：李倩君[1] 潘峰[1] 王丙剑[1] 朱进[2] 张建民[3] 吴亚夫[3] 周传文[1] 

机构地区：[1]南京医科大学附属淮安第一医院消化病科,江苏省223300 [2]南京军区军事医学研究所 [3]南京医科大学鼓楼临床医学院肝胆外科

出　　处：《江苏医药》2013年第5期506-508,F0002,共4页Jiangsu Medical Journal

基　　金：南京医科大学科技发展基金重点项目(2011NJMU241)

摘　　要：目的检测抗血管内皮生长因子受体2(VEGFR-2)嵌合Fab抗体对裸鼠肝癌原位移植瘤的治疗作用。方法 40只4周龄雄性BALB/c裸鼠建立肝癌H22细胞移植瘤模型后随机均分为Fab抗体(A)组和生理盐水对照(B)组。比较两组裸鼠生存时间、移植瘤病理变化及微血管密度(MVD)。结果成功建立裸鼠H22肝癌原位移植瘤模型,HE染色显示肝细胞肝癌。A组裸鼠中位数生存时间明显长于B组(20.0dvs.14.0d)(P<0.01);A组肝脏实体瘤内MVD较B组显著减少(8.65±1.79vs.25.64±1.53)(P<0.05)。结论抗VEGFR-2嵌合Fab抗体对裸鼠肝癌原位移植瘤有治疗作用。Objective To investigate the therapeutical effect of chimeric anti-vascular endothelial growth factor receptor（VEGFR）-2 Fab antibody on orthotopie xenograft in BALB/c nude mice. Methods The orthotopic xenograft model of hepatocellular carcinoma H22 cells was established in 40 nude mice, which were equally randomized into two groups of A（treated with chimeric anti- VEGFR-2 Fab antibody） and B（treated with normal saline）. The survival time, pathological changes and microvessel density（MVD） in H22 xenografts were compared between two groups. Results An orthotopic xenograft model of hepatocellular carcinoma was successfully created in nude mice, which was confermed as hepatocellular carcinoma by hematoxylin-eosin staining. The mean survival time was longer in group A than that in group B（20. 0 d vs. 14. 0 d） （P〈0. 05）. MVD in the xenografts was less in group A than that in group B（8. 65±1.79 vs. 25.64±1.53）（P〈0. 05）. Conclusion The chimeric anti-VEGFR-2 Fab antibody has some therapeutical effect on an orthotopic xenografts in nude mice.

关 键 词：肝癌 血管内皮生长因子受体2 嵌合Fab抗体 

分 类 号：R735[医药卫生—肿瘤]